Skip to main content

Table 1 Patient characteristics and outcome

From: Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration

  Treated with bevacizumab (N = 5385)
N (%)
Not treated with bevacizumab (N = 10,756)
N (%)
P-value
Age Start [mean ± SD] 81.17 ± 8.91 80.88 ± 8.91 .051
Male 2460 (45.7) 4916 (45.7) .979
Married 2180 (40.5) 4637 (43.1) < .001
Socioeconomic statusa    <.001
 High 1213 (22.6) 2910 (27.1)  
 Medium 2510 (46.7) 4620 (43.1)  
 Low 1652 (30.7) 3190 (29.8)  
Cataract 2353 (43.7) 3585 (35.9) < .001
Smoking 1008 (18.7) 1555 (14.5) < .001
Alcohol 27 (.05) 64 (.06) .524
Hypertension 4142 (76.9) 7666 (71.3) < .001
Diabetes mellitus 1821 (33.8) 3019 (28.1) < .001
Obesity 1413 (26.2) 2581 (24.0) < .001
Congestive heart failure 538 (10.0) 893 (8.3) < .001
Liver cancer 4 (.01) 6 (.01) .913
Ischemic heart disease 2030 (37.7) 3434 (31.9) < .001
Cerebrovascular accident 857 (15.9) 1508 (14.0) < .001
Mortality 1063 (19.7) 1298 (12.1) < .001
  1. a Mann-Whitney test